Search

Your search keyword '"Ninomiya, Hironori"' showing total 372 results

Search Constraints

Start Over You searched for: Author "Ninomiya, Hironori" Remove constraint Author: "Ninomiya, Hironori"
372 results on '"Ninomiya, Hironori"'

Search Results

9. Minimally invasive surgery for intradiaphragmatic bronchogenic cyst

16. Ex-vivo 1.5T MR Imaging versus CT in Estimating the Size of the Pathologically Invasive Component of Lung Adenocarcinoma Spectrum Lesions

17. Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity

19. MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF

24. Resurgence of morphology: Discarded small cell lung carcinoma subtypes reflect current molecular classification.

25. Clinical characteristics of patients with KRAS mutation detected by liquid biopsy

26. Prediction of Tumor PD-L1 Expression in Resectable Non-Small Cell Lung Cancer by Machine Learning Models Based on Clinical and Radiological Features: Performance Comparison With Preoperative Biopsy

30. Insulinoma-associated Protein 1 (INSM1) Is a Better Marker for the Diagnosis and Prognosis Estimation of Small Cell Lung Carcinoma Than Neuroendocrine Phenotype Markers Such as Chromogranin A, Synaptophysin, and CD56

32. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer

33. Data from Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status

34. Supplemental materials and methods from Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status

35. FigureS1-S9, TableS1 from Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status

40. Combination of epidermal growth factor receptor mutation and the presence of high-grade patterns is associated with recurrence in resected stage I lung adenocarcinoma

41. Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation

45. Standard therapy‑resistant small cell lung cancer showing dynamic transition of neuroendocrine fate during the cancer trajectory: A case report

47. Pulmonary adenocarcinoma with mucin production and possible subtyping based on driver mutations and transcription factors

50. Machine learning‐based gene alteration prediction model for primary lung cancer using cytologic images.

Catalog

Books, media, physical & digital resources